Corel Medical Series: Cancer/Corel Medical Series: Cancer.iso/mac/Program/Indexdat/indexa.M

Text File | 1997-01-27 | 6KB | 2 lines

Maalox,p06.18,Macrophages,p08.3;p08.5,Magic bullet,p07.2,Magnesium,p17.24,Magnesium citrate,p17.24,Magnetic resonance imaging (MRI),p01.3;p02.15,Major Medical Coverage,p32a.4,Malabsorption of nutrients,p18.3,Malignant mixed mesodermal tumor uterus,c45.2;c45.4,Malnutrition,p18.5,Mammography,p34.18;c06.8,Managed care plans,p32a.5,Mantle cell lymphoma,c24.14,Marijuana,p17.14;chr.p17.14;p17.20;c16.22,Marinol,p17.14;p17.20;c16.22,Masoprocol cream,c37.16,Mastectomy,6,Matulane,chr.p17.13;c08.13,Mechlorethamine,c23.16;c23.17,Mediastinoscopy,p04.9,Medicaid defined,p32a.4,Medical codes,p32.3,Medicare defined,p32a.3,Medigap defined,p32a.4,Meditation,p25.8,MEDLARS (Medical Literature Analysis and Retrieval System),p37.16,Medullary carcinoma,2,Medullary thyroid cancer,c01.6,Medulloblastoma,2,Megace,p17.20;c06.26;c29.21;c35.29;c44.20,Megakaryocytic leukemia,c18.29,Megavoltage equipment,p06.7,Melanoma,23,Melphalan,8,Meningioma,c05.1;c05.18;c05.23;c10b.2,Meningitis,p20.5,Mercaptopurine,chr.p17.13,Meritine,p18.12,Mesna,c24.20;c29.21;c40.17;c46.13,Mesothelioma,13,Metabolic therapies unproven,p13.10,Metaclopramide,chr.p17.14,Metamucil,p17.24;p17.31,Metastases,5,Metastatic cancer,10,Methadone,p19.8;p19.13,Methotrexate,16,Methyl cellulose,p17.24,Methylprednisolone,c28.20,Metoclopramide,c12.26,Microsurgical free flap technique breast reconstruction,rec.6,Midline tumor unknown primary site,c07.13,Milk intolerance,p17.30,Milk of magnesia,p17.24,Mineral oil,p17.25,Minerals,p13.10;p34.7,Mitoguazone,p35.9,Mitomycin-C,16,Mitotane,c01.10;c01.12;c01.13,Mitoxantrone,8,Mixed cell cancer parathyroid,c32.2,Mixed ductal carcinoma,c35.32,Mixed mesodermal sarcoma uterus,c45.2;c45.4;c45.10,Mohs micrographic surgery,c37.17,Moistir,p17.17,Molar pregnancy,c43.2;c43.12,Mole,4,Monoamine oxidase inhibitors,c08.13,Monoclonal gammopathy of undetermined significance,c28.6,Monocytes,p04.5,Monocytoid B-cell lymphoma,c24.14,Morphine,p17.23;p19.8;p19.13;p27.6,Mouth diagram,c14b.1,Mouth care,p17.16;p26.10;c14a.5,Mouth tumor,c14a.1;c14b.1,MouthKot,p17.17,Mucinous carcinoma,2,Mucoepidermoid anal cancer,c02.1,Mucosa-associated lymphoma,c24.14,Multiple endocrine neoplasia (MEN),6,Multiple hit theory,p01.6;p34.5;p36.4,Multiple myeloma,12,Muscle ache,p08.17,Muscle invasive tumor,c04.4,Muscle weakness,c28.18,Myasthenia gravis,c41.2;c41.4;c41.5;c41.6;c41.8,Mycelex Troches,p17.18,Mycostat Pastilles,p17.18,Mycostatin,p17.18;p18.15;p18.17,Myelodysplastic syndrome,c18.12,Myelogenous leukemia,p36.8,Mylanta,p06.18;p17.18,Myleran,c18.13;c18.24,
male,c06.49,prophylactic,p05.3,radical,c06.20,risk of lymphangiosarcoma,c36.4,and sexuality,p23.9,treatment,c06.19;c06.29,breast,c06.4,thyroid,c42.2;c42.22,adult,c05.10;c05.17,child,c10a.2;c10b.2;c10b.8;c10b.10,anus,c02.2;c25.3,brain,c25.3,causes,c25.4,child,c10a.2,colorectal,c11a.2,defined,c25.1,diagnosis,c25.9,diagram,c25.11,esophagus,c12.2,mouth,c25.3,penis,c33.1,questions to ask,c25.28,recurrence,c25.24,risk factors,c25.5,screening,c25.7,spread,c25.3,staging,c25.11,symptoms,c25.8,treatment,c25.15,types,c25.2,unknown primary site,c07.4,vagina,c25.3;c46.1;c46.13,vulva,c47.2;c47.17,for Hodgkin's disease,c23.17,for melanoma,c25.15,for multiple myeloma,c28.12;c28.20,for ovarian cancer,c29.20;c29.24,in hyperthermia,p10.3,in hyperthermic perfusion,p11.5,potentiated by buthionine sulfoximine,p35.18,side effects,chr.p17.13,causes,c26.2,defined,c26.1,diagnosis,c26.7,diagram,c26.2,follow-up,c26.17,questions to ask,c26.18,risk factors,c26.4,screening,c26.5,spread,c26.2,staging,c26.10,symptoms,c26.6,treatment,c26.11,types,c26.1,bone,c27.3;c27.10,brain,c27.3;c27.7,defined,p01.4,liver,c27.3;c27.11,lung,c27.3;c27.9,causes,c27.2,defined,c27.1,diagnosis,c27.4,diagram,c27.7,follow-up,c27.15,questions to ask,c27.16,spread,c27.2,symptoms,c27.3,treatment,c27.7,types,c27.1,for bladder cancer,c04.24,for bone and soft tissue sarcomas,c36.11;c36.12;c36.13,for breast cancer,c06.24;c06.37;c06.39,for Hodgkin's disease,c23.15,for Kaposi's sarcoma,c16.16,for lymphoma,c22.7;c24.19,for mesothelioma,c26.11,for osteogenic sarcoma,c10d.8,for stomach cancer,c39.15;c39.16,for trophoblastic disease,c43.13;c43.14,for uterine cancer,c44.21,for vaginal cancer,c46.12;c46.15,for vulvar cancer,c47.15,in chemotherapy,p07.6,related drugs,p35.8;p35.13;p35.18,side effects,chr.p17.13,for anal cancer,c02.9;c02.13;c02.14,for bile duct cancer,c03.11,for bladder cancer,c04.18,for breast cancer,c06.48,for cervical cancer,c09.19;c09.22;c09.24,for colorectal cancer,c11b.18;c11c.11,for esophageal cancer,c12.14;c12.17;c12.20,for gall bladder cancer,c13.11;c13.14;c13.15,for liver cancer,c19.11,for lung cancer,c20.18,for pancreatic cancer,c31.11;c31.17,for stomach cancer,c39.15;c39.19,for vaginal cancer,c46.10;c46.12;c46.15,for vulvar cancer,c47.9;c47.11;c47.13;c47.14;c47.15,in hyperthermia,p10.3,side effects,chr.p17.13,for bladder cancer,c04.18,for leukemia,c18.18,for liver cancer,c19.11,for ovarian cancer,c29.20,for uterine cancer,c44.13;c44.16;c44.17;c44.20;c44.21;c45.12;c45.14,for vaginal cancer,c46.12;c46.15,related drugs,p35.10,side effects,chr.p17.13,benign,p01.4,invasive,c43.1;c43.2;c43.3;c43.8,malignant,c25.1,warning signals,c25.8,breast,c06.2;c06.4,ovary,c29.1,adrenal gland cancer,c01.6,gastrointestinal tract cancer,c08.2,islet cell carcinoma,c15.3,parathyroid cancer,c32.2;c32.3,risk factor,c15.3,thyroid cancer,c42.2;c42.6,causes,c28.3,defined,c28.1,diagnosis,c28.8,diagram,c28.17,questions to ask,c28.21,recurrent,c28.20,risk factors,c28.5,screening,c28.6,staging,c28.11,symptoms,c28.7,treatment,p12.23;c28.12,types,c28.1,